Skip to main content

Peer Review reports

From: Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA)

Original Submission
23 Jun 2021 Submitted Original manuscript
30 Nov 2021 Reviewed Reviewer Report
13 Dec 2021 Reviewed Reviewer Report
24 Dec 2021 Author responded Author comments - Changjun Wang
Resubmission - Version 2
24 Dec 2021 Submitted Manuscript version 2
17 Jan 2022 Reviewed Reviewer Report
25 Jan 2022 Reviewed Reviewer Report
25 Feb 2022 Author responded Author comments - Changjun Wang
Resubmission - Version 3
25 Feb 2022 Submitted Manuscript version 3
Publishing
28 Feb 2022 Editorially accepted
14 Mar 2022 Article published 10.1186/s12885-022-09346-1

You can find further information about peer review here.

Back to article page